Sarepta Therapeutics (MEX:SRPT) Cyclically Adjusted Book per Share: MXN202.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN294.00
GF Value MXN2,058.94
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Cyclically Adjusted Book per Share?

Sarepta Therapeutics MEX:SRPT 36 Cyclically Adjusted Book per Share is MXN202.17 as of Mar. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,058.94 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was MXN257.088. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN202.17 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sarepta Therapeutics's average Cyclically Adjusted Book Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 7.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Sarepta Therapeutics was 27.80% per year. The lowest was -15.20% per year. And the median was 3.40% per year.

As of today (2026-07-14), Sarepta Therapeutics's current stock price is MXN294.00. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN202.17. Sarepta Therapeutics's Cyclically Adjusted PB Ratio of today is 1.45.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sarepta Therapeutics was 38.73. The lowest was 1.05. And the median was 12.01.


Sarepta Therapeutics  (MEX:SRPT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sarepta Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=294.00/202.17
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sarepta Therapeutics was 38.73. The lowest was 1.05. And the median was 12.01.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sarepta Therapeutics Cyclically Adjusted Book per Share Related Terms


Sarepta Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Cyclically Adjusted Book per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 215.67

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362.64 227.22 212.62 215.67 202.17

MEX:SRPT vs ZYME, BCAX, INVA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.


MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=257.088/330.2130*330.2130
=257.088

Current CPI (Mar. 2026) = 330.2130.

Sarepta Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 46.923 241.018 64.288
201609 145.366 241.428 198.824
201612 126.766 241.432 173.381
201703 147.073 243.801 199.201
201706 123.391 244.955 166.338
201709 195.951 246.819 262.158
201712 239.224 246.524 320.435
201803 215.471 249.554 285.114
201806 207.035 251.989 271.304
201809 179.454 252.439 234.742
201812 285.186 251.233 374.840
201903 352.867 254.202 458.381
201906 284.062 256.143 366.205
201909 263.705 256.759 339.146
201912 205.241 256.974 263.736
202003 344.338 258.115 440.520
202006 306.910 257.797 393.122
202009 250.111 260.280 317.312
202012 190.905 260.474 242.018
202103 137.245 264.877 171.099
202106 120.964 271.696 147.017
202109 120.742 274.310 145.349
202112 218.499 278.802 258.790
202203 194.997 287.504 223.964
202206 166.960 296.311 186.062
202209 98.744 296.808 109.857
202212 85.332 296.797 94.939
202303 137.935 301.836 150.903
202306 136.272 305.109 147.484
202309 142.342 307.789 152.712
202312 155.620 306.746 167.525
202403 168.824 312.332 178.489
202406 207.089 314.175 217.660
202409 251.780 315.301 263.688
202412 328.815 315.605 344.034
202503 237.932 319.799 245.680
202506 261.586 322.561 267.792
202509 231.144 324.800 234.996
202512 195.664 324.054 199.383
202603 257.088 330.213 257.088

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN202.17 mean?
Sarepta Therapeutics (MEX:SRPT) has a Cyclically Adjusted Book per Share of MXN202.17 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Cyclically Adjusted Book per Share too high?
Sarepta Therapeutics' current Cyclically Adjusted Book per Share is MXN202.17. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Cyclically Adjusted Book per Share compare to ZYME and BCAX?
Sarepta Therapeutics' Cyclically Adjusted Book per Share of MXN202.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Cyclically Adjusted Book per Share is MXN202.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,058.94, compared to a current price of MXN294.00 — trading 85.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN202.17. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Cyclically Adjusted Book per Share is MXN202.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 85.7% below its estimated GF Value™ of MXN2,058.94. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Cyclically Adjusted Book per Share: MXN202.17
  • GF Value™: MXN2,058.94 vs. price of MXN294.00 (85.7% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,058.94
GF Value